Logo image of LIFE

ATYR PHARMA INC (LIFE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LIFE - US0021202025 - Common Stock

1.9 USD
+0.05 (+2.7%)
Last: 6/4/2024, 8:12:25 PM
1.94 USD
+0.04 (+2.11%)
After Hours: 6/4/2024, 8:12:25 PM
Fundamental Rating

2

Taking everything into account, LIFE scores 2 out of 10 in our fundamental rating. LIFE was compared to 528 industry peers in the Biotechnology industry. LIFE has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LIFE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year LIFE has reported negative net income.
  • LIFE had a negative operating cash flow in the past year.
  • In the past 5 years LIFE always reported negative net income.
  • In the past 5 years LIFE always reported negative operating cash flow.
LIFE Yearly Net Income VS EBIT VS OCF VS FCFLIFE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -47.62%, LIFE is in line with its industry, outperforming 49.74% of the companies in the same industry.
  • The Return On Equity of LIFE (-63.85%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROIC N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
LIFE Yearly ROA, ROE, ROICLIFE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LIFE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIFE Yearly Profit, Operating, Gross MarginsLIFE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

  • LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LIFE has more shares outstanding
  • The debt/assets ratio for LIFE is higher compared to a year ago.
LIFE Yearly Shares OutstandingLIFE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
LIFE Yearly Total Debt VS Total AssetsLIFE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • LIFE has an Altman-Z score of -4.12. This is a bad value and indicates that LIFE is not financially healthy and even has some risk of bankruptcy.
  • LIFE has a Altman-Z score of -4.12. This is in the lower half of the industry: LIFE underperforms 61.18% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that LIFE is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.02, LIFE perfoms like the industry average, outperforming 44.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACC8.87%
LIFE Yearly LT Debt VS Equity VS FCFLIFE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 6.07 indicates that LIFE has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.07, LIFE is in the better half of the industry, outperforming 60.66% of the companies in the same industry.
  • LIFE has a Quick Ratio of 6.07. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.07, LIFE is doing good in the industry, outperforming 61.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.07
Quick Ratio 6.07
LIFE Yearly Current Assets VS Current LiabilitesLIFE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

  • LIFE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.93%, which is quite impressive.
  • Looking at the last year, LIFE shows a very negative growth in Revenue. The Revenue has decreased by -94.34% in the last year.
  • The Revenue for LIFE have been decreasing by -67.68% on average. This is quite bad
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LIFE will show a very strong growth in Earnings Per Share. The EPS will grow by 35.04% on average per year.
  • Based on estimates for the next years, LIFE will show a very strong growth in Revenue. The Revenue will grow by 291.57% on average per year.
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LIFE Yearly Revenue VS EstimatesLIFE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
LIFE Yearly EPS VS EstimatesLIFE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LIFE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIFE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIFE Price Earnings VS Forward Price EarningsLIFE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIFE Per share dataLIFE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • LIFE's earnings are expected to grow with 26.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y26.27%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for LIFE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATYR PHARMA INC

NASDAQ:LIFE (6/4/2024, 8:12:25 PM)

After market: 1.94 +0.04 (+2.11%)

1.9

+0.05 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02
Earnings (Next)08-07
Inst Owners69.81%
Inst Owner Change0%
Ins Owners12.06%
Ins Owner Change0%
Market Cap129.87M
Revenue(TTM)588.00K
Net Income(TTM)-53.93M
Analysts81.82
Price Target25.09 (1220.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.74%
Min EPS beat(2)-2.98%
Max EPS beat(2)4.45%
EPS beat(4)3
Avg EPS beat(4)9.32%
Min EPS beat(4)-2.98%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)12.77%
EPS beat(12)7
Avg EPS beat(12)6.02%
EPS beat(16)10
Avg EPS beat(16)4.78%
Revenue beat(2)1
Avg Revenue beat(2)475.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)1051.96%
Revenue beat(4)1
Avg Revenue beat(4)193.76%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)2
Avg Revenue beat(8)641.07%
Revenue beat(12)2
Avg Revenue beat(12)394.04%
Revenue beat(16)4
Avg Revenue beat(16)382.04%
PT rev (1m)8.85%
PT rev (3m)10.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)2.81%
EPS NY rev (3m)-7.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-84.63%
Revenue NY rev (3m)-95.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 220.87
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.01
BVpS1.24
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 432.17%
Cap/Sales 507.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.07
Quick Ratio 6.07
Altman-Z -4.12
F-Score1
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)486.58%
Cap/Depr(5y)301.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
EBIT growth 1Y-25.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.85%
EBIT Next 3Y43.39%
EBIT Next 5Y48.12%
FCF growth 1Y-54.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.21%
OCF growth 3YN/A
OCF growth 5YN/A

ATYR PHARMA INC / LIFE FAQ

What is the ChartMill fundamental rating of ATYR PHARMA INC (LIFE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LIFE.


Can you provide the valuation status for ATYR PHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to ATYR PHARMA INC (LIFE). This can be considered as Overvalued.


What is the profitability of LIFE stock?

ATYR PHARMA INC (LIFE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ATYR PHARMA INC?

The Earnings per Share (EPS) of ATYR PHARMA INC (LIFE) is expected to grow by 2.52% in the next year.